James R. Helvey, III
About James R. Helvey, III
Independent director since 2016; age 66; Managing Partner at Cassia Capital Partners (co‑founded in 2011). Former JP Morgan executive (risk and trading leadership across US, Europe, Asia), CEO of Cygnifi Derivatives Services, and Partner/Risk Management Officer at CMT Asset Management. Education: Wake Forest University (magna cum laude), Fulbright Scholar (University of Cologne), master’s in international finance and banking from Columbia University SIPA (International Fellow). Designated Audit Committee Financial Expert by COKE’s Board.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Cassia Capital Partners, LLC | Managing Partner | 2011–present | Co‑founder; registered investment adviser leadership |
| CMT Asset Management Limited | Partner & Risk Management Officer | 2005–2011 | Firm‑wide risk oversight |
| Cygnifi Derivatives Services, LLC | Chairman & CEO | 2000–2002 | Led online derivatives services provider |
| J.P. Morgan & Co. | Senior roles (Liquidity Committee Chair; Risk Management Committee Vice Chair; Global Head of Derivative Counterparty Risk; swap/FX trading leads in Asia/Europe) | 1985–2000 | Enterprise risk governance; global trading leadership |
| U.S. Congress (NC 5th District) | Candidate | 2003–2004 | Public policy exposure |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Piedmont Federal Bank | Director | Current | Community bank board oversight |
| Verger Capital Management LLC | Advisory Board Member (prior Board Director) | Current (prior service) | Investment oversight; prior board governance |
| Computer Task Group, Inc. | Director; Chair of Board; Chair of Audit Committee | 2015–2023 | Led board and audit oversight (IT services firm) |
| Pike Corporation | Director; Lead Independent Director; Chair of Audit & Compensation | 2005–2014 | Independent leadership; committee governance (energy solutions) |
| Wake Forest University | Board service | Prior | Institutional governance |
| Wake Forest Baptist Medical Center | Board service | Prior | Health system governance |
Board Governance
- Independence and role: Board determined Helvey is independent; he serves on the Audit Committee and is designated an Audit Committee Financial Expert. Audit held 4 meetings in fiscal 2024.
- Committee assignments: Audit Committee Member; not a committee chair.
- Attendance and engagement: All incumbents attended ≥75% of Board/committee meetings in fiscal 2024; 11 of 12 directors participated in the 2024 Annual Meeting (virtual).
- Lead Independent Director: Dennis A. Wicker reappointed as Lead Independent Director in March 2025; independent sessions occur at least twice per year.
- Controlled company context: COKE is a Nasdaq “controlled company” (controlling stockholder J. Frank Harrison, III) and uses Executive Committee for nominations with controlling stockholder approval; The Coca‑Cola Company has one board designee (Elaine Bowers Coventry).
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Fees Earned or Paid in Cash ($) – Helvey | $194,800 | $196,400 |
| Base annual retainer for non‑employee directors ($) | $190,000 | $190,000 |
| Committee meeting fee per meeting ($) | $1,600 | $1,600 |
| Chair retainers (Audit / Compensation / Lead Independent) ($) | $20,000 / $15,000 / $20,000 | $20,000 / $15,000 / $20,000 |
| Director Deferral Plan availability | Yes (fee deferral; mutual fund tracking) | Yes (fee deferral; mutual fund tracking) |
Notes: Employee directors do not receive director fees; Helvey is a non‑employee director.
Performance Compensation
| Component | Status |
|---|---|
| Performance‑based pay for directors (RSUs/PSUs/options) | None disclosed; director compensation consists of cash retainers/fees with optional deferral. |
Other Directorships & Interlocks
| Area | Detail |
|---|---|
| Supplier/customer/competitor interlocks | None disclosed for Helvey; The Coca‑Cola Company maintains agreements and a designated director separate from Helvey. |
| Related person transactions | Audit Committee reviews/approves related person transactions; disclosures identify items tied to other directors/executives, not Helvey. |
Expertise & Qualifications
- Financial oversight: Audit Committee Financial Expert designation (SEC definition) underscores deep accounting/controls literacy.
- Risk management: Former chair/vice chair of JP Morgan risk committees; global trading and counterparty risk leadership.
- Education: Wake Forest (magna cum laude), Fulbright Scholar (University of Cologne), Columbia SIPA master’s (International Fellow).
Equity Ownership
| Holder | Class | Shares Beneficially Owned | % of Class |
|---|---|---|---|
| James R. Helvey, III | Common Stock | — | <1% |
Context: As of March 17, 2025, 7,713,088 Common and 1,004,696 Class B shares were outstanding. Hedging/short selling prohibited; pledging in margin accounts prohibited for directors/officers.
Governance Assessment
-
Strengths
- Independent director with audit financial expert designation on a board where independent oversight is critical under controlled company status.
- Broad external board experience (chair, lead independent, audit and compensation chair roles) indicating governance sophistication.
- Board mandates executive sessions for independents and maintains clear related‑party review protocols via Audit Committee.
- Attendance compliance (≥75%) indicates baseline engagement.
-
Potential concerns and investor signals
- Controlled company structure centralizes nomination and board leadership under controlling stockholder; investors should monitor independence in practice and Executive Committee nomination process.
- Ownership alignment: No reported common stock ownership for Helvey; absence of equity compensation for directors may reduce “skin‑in‑the‑game.”
- While related‑party exposures exist at COKE (e.g., leases with entities tied to controlling stockholder), none are attributed to Helvey; continued vigilance warranted given Audit Committee’s oversight role.
-
Policy safeguards
- Insider Trading Policy prohibits hedging/short selling and margin pledging; company adopted an incentive‑based compensation recovery (clawback) policy effective Aug 1, 2023.